Key Takeaways
- • Blackstone and TPG completed the acquisition of Hologic at approximately $79 per share including contingent value rights (CVRs), representing an $18.3 billion transaction that closed on April 7, 2026, taking the medical technology company private.
- • The deal marks a significant inflection point in large-scale private equity dealmaking, signaling the return of mega-cap "take-private" transactions following nearly two years of elevated interest rates and constrained financing conditions.
- • Hologic's women's health diagnostics and medical imaging portfolio—spanning breast health, molecular diagnostics, and surgical solutions—offers Blackstone and TPG exposure to secular healthcare demand drivers including aging populations, rising chronic disease incidence, and increasing global healthcare investment.
- • The acquisition reflects private equity's strategic pivot toward healthcare and med-tech sectors where public market valuations have diverged from intrinsic value, with diagnostic and imaging technologies providing recurring revenue streams and high-margin service opportunities.
- • José Almeida, former Baxter chief executive, assumed leadership of Hologic following the transaction's completion, positioning the company under new operational management as it transitions to private ownership.
Summary
Blackstone and TPG have officially completed their acquisition of Hologic, closing the $18.3 billion transaction on April 7, 2026. The deal, valued at approximately $79 per share including contingent value rights, represents one of the year's most significant healthcare buyouts and signals a decisive reactivation of large-scale private equity dealmaking following an extended period of market dislocation. This transaction underscores the return of mega-cap "take-private" strategies as leading firms resume aggressive capital deployment after nearly two years of elevated interest rates and tightened financing conditions.
Hologic's acquisition reflects a broader strategic inflection within private equity toward healthcare and medical technology sectors. The Marlborough, Massachusetts-based company operates as a global leader in women's health diagnostics and medical imaging, with core competencies spanning breast health, molecular diagnostics, and surgical solutions. These market segments benefit from powerful demographic tailwinds—including aging populations and rising chronic disease prevalence—alongside structural increases in global healthcare investment and technology adoption.
The investment thesis centers on healthcare's inherent resilience relative to more cyclical industries. Diagnostic and imaging technologies have become increasingly central to modern healthcare delivery systems, generating durable, recurring revenue streams and high-margin service opportunities. Unlike discretionary sectors, healthcare demand remains relatively inelastic, driven by long-term demographic necessity rather than economic cycles. This characteristic has made medical technology an attractive target for institutional capital seeking stability and predictable cash generation in a normalization environment.
Leadership continuity marks another component of the transition. José Almeida, who previously served as chief executive of Baxter, assumed the helm at Hologic following the acquisition's completion, positioning the company under experienced operational management as it navigates its transition to private ownership. This deal exemplifies how private equity's return to scale in healthcare reflects confidence in both sector fundamentals and the ability to unlock value through operational enhancement and strategic repositioning within a private structure.
Hologic's acquisition reflects a broader strategic inflection within private equity toward healthcare and medical technology sectors. The Marlborough, Massachusetts-based company operates as a global leader in women's health diagnostics and medical imaging, with core competencies spanning breast health, molecular diagnostics, and surgical solutions. These market segments benefit from powerful demographic tailwinds—including aging populations and rising chronic disease prevalence—alongside structural increases in global healthcare investment and technology adoption.
The investment thesis centers on healthcare's inherent resilience relative to more cyclical industries. Diagnostic and imaging technologies have become increasingly central to modern healthcare delivery systems, generating durable, recurring revenue streams and high-margin service opportunities. Unlike discretionary sectors, healthcare demand remains relatively inelastic, driven by long-term demographic necessity rather than economic cycles. This characteristic has made medical technology an attractive target for institutional capital seeking stability and predictable cash generation in a normalization environment.
Leadership continuity marks another component of the transition. José Almeida, who previously served as chief executive of Baxter, assumed the helm at Hologic following the acquisition's completion, positioning the company under experienced operational management as it navigates its transition to private ownership. This deal exemplifies how private equity's return to scale in healthcare reflects confidence in both sector fundamentals and the ability to unlock value through operational enhancement and strategic repositioning within a private structure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.